Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Short-term Investments (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Short-term Investments for 4 consecutive years, with $244.0 million as the latest value for Q4 2025.

  • Quarterly Short-term Investments fell 40.0% to $244.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $244.0 million through Dec 2025, down 40.0% year-over-year, with the annual reading at $244.0 million for FY2025, 40.0% down from the prior year.
  • Short-term Investments for Q4 2025 was $244.0 million at Day One Biopharmaceuticals, down from $408.3 million in the prior quarter.
  • The five-year high for Short-term Investments was $439.7 million in Q1 2025, with the low at $47.6 million in Q1 2024.
  • Average Short-term Investments over 4 years is $253.9 million, with a median of $253.6 million recorded in 2022.
  • The sharpest move saw Short-term Investments tumbled 82.32% in 2024, then soared 824.57% in 2025.
  • Over 4 years, Short-term Investments stood at $257.0 million in 2022, then tumbled by 47.25% to $135.6 million in 2023, then surged by 200.05% to $406.8 million in 2024, then tumbled by 40.0% to $244.0 million in 2025.
  • According to Business Quant data, Short-term Investments over the past three periods came in at $244.0 million, $408.3 million, and $417.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.